BioRestorative Therapies, Inc. (BRTX) presents a deeply negative liquidation posture as of December 31, 2025. Total assets of $4.08M face $3.72M in current liabilities, yielding GAAP book equity of $357K — but under liquidation haircuts, recovery to equity is negative. Liquid assets consist of $1.51M cash (100% recovery = $1.51M), $1.44M in Level 1 marketable securities (100% recovery = $1.44M), $15.5K net AR (90% = $14K), and $168K prepaid/other (0-20% recovery, minimal). PP&E gross of $1.59M with $1.23M accumulated depreciation yields net $359K, worth perhaps $180-250K at 50-70% liquidation haircut. Intangibles net $534K (licensed technology and patents) recover $0 under liquidation assumptions — the entire carrying value evaporates. Total liquidating asset value approximates $3.2-3.3M before liability settlement. Against this, current liabilities of $3.72M must be settled at face: accounts payable $1.34M, accrued expenses $982K (including $714K accrued bonuses — a hard cash obligation on wind-down), derivative warrant liabilities $1.40M (mark-to-market Level 3, but face-value treatment applies), and $50K deferred offering costs offset. No long-term debt. No operating lease liability (Melville lease expired December 31, 2024; company is on month-to-month, no ROU asset or lease liability on balance sheet). Net liquidation recovery to equity is negative: approximately ($400K) to ($500K) before transaction costs, consistent with MFFAIS CLV of ($2.2M) which likely applies more conservative haircuts. The company carries $169.9M accumulated deficit and a $14.2M pre-tax loss for fiscal 2025, up materially from $9.0M in 2024, driven by escalating R&D spend ($10.1M vs. $6.7M prior year) tied to Phase 2 clinical trial costs, plus $3.3M non-cash stock comp. Full deferred tax valuation allowance of $22.6M confirms no tax asset recovery. Post-period, a $5M gross proceeds public offering (February 13, 2026, Rodman) and conversion of all Series B preferred temporarily improves cash but does not alter the structural liquidation deficit. Revenue of $360K annually (royalties plus Cartessa supply agreement) is immaterial against the $16M operating expense run rate. Filing discloses material weaknesses in internal controls over financial reporting, adding execution risk to any restructuring scenario. No goodwill. No pension. Warrant derivative liability ($1.40M, Level 3 Black-Scholes) is the most judgment-dependent liability and could shift materially with stock price movement.
▼ Community Notes